International Journal of Cancer Management

Published by: Kowsar

Economic Evaluation of Treatments for Patients with Esophageal Cancer: A Systematic Review

Ahmad Faramarzi ORCID 1 , Rajabali Daroudi ORCID 1 , Azin Nahvijou ORCID 2 , Ali Akbar Sari ORCID 1 , Mohammad Arab ORCID 1 , * and Bita Kalaghchi ORCID 3
Authors Information
1 Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
3 Radiation Oncology Research Center, Tehran, Iran
Article information
  • International Journal of Cancer Management: March 31, 2019, 12 (3); e86631
  • Published Online: March 17, 2019
  • Article Type: Systematic Review
  • Received: November 21, 2018
  • Revised: March 6, 2019
  • Accepted: March 9, 2019
  • DOI: 10.5812/ijcm.86631

To Cite: Faramarzi A, Daroudi R, Nahvijou A , Sari A A, Arab M, et al. Economic Evaluation of Treatments for Patients with Esophageal Cancer: A Systematic Review, Int J Cancer Manag. 2019 ; 12(3):e86631. doi: 10.5812/ijcm.86631.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Objectives
3. Data Sources
4. Results
5. Discussion
6. Conclusions
  • 1. Li L, Zhang C, Li X, Lu S, Zhou Y. The candidate tumor suppressor gene ECRG4 inhibits cancer cells migration and invasion in esophageal carcinoma. J Exp Clin Cancer Res. 2010;29:133. doi: 10.1186/1756-9966-29-133. [PubMed: 20937111]. [PubMed Central: PMC2958930].
  • 2. Li T, Suo Q, He D, Du W, Yang M, Fan X, et al. Esophageal cancer risk is associated with polymorphisms of DNA repair genes MSH2 and WRN in Chinese population. J Thorac Oncol. 2012;7(2):448-52. doi: 10.1097/JTO.0b013e31823c487a. [PubMed: 22173703].
  • 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492. [PubMed: 30207593].
  • 4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi: 10.3322/caac.20073. [PubMed: 20610543].
  • 5. Mirinezhad SK, Somi MH, Jangjoo AG, Seyednezhad F, Dastgiri S, Mohammadzadeh M, et al. Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev. 2012;13(7):3451-4. doi: 10.7314/APJCP.2012.13.7.3451. [PubMed: 22994776].
  • 6. Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, et al. Cancer survival in China, 2003-2005: A population-based study. Int J Cancer. 2015;136(8):1921-30. doi: 10.1002/ijc.29227. [PubMed: 25242378].
  • 7. Kim HL, Puymon MR, Qin M, Guru K, Mohler JL. NCCN Clinical practice guidelines in oncology™. J Natl Compr Cancer Netw. 2013.
  • 8. Martin-Richard M, Diaz Beveridge R, Arrazubi V, Alsina M, Galan Guzman M, Custodio AB, et al. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 2016;18(12):1179-86. doi: 10.1007/s12094-016-1577-y. [PubMed: 27900538]. [PubMed Central: PMC5138258].
  • 9. National Guideline Alliance (UK). Oesophago-gastric cancer: Assessment and management in adults. London: National Institute for Health and Care Excellence: Clinical Guidelines; 2018. Contract No.: 1473127920.
  • 10. Gordon LG, Hirst NG, Mayne GC, Watson DI, Bright T, Cai W, et al. Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia. J Gastrointest Surg. 2012;16(8):1451-61. doi: 10.1007/s11605-012-1911-9. [PubMed: 22644445].
  • 11. Arlow RL, Moore DF, Chen C, Langenfeld J, August DA. Outcome-volume relationships and transhiatal esophagectomy: Minimizing "failure to rescue". Ann Surg Innov Res. 2014;8(1):9. doi: 10.1186/s13022-014-0009-3. [PubMed: 25550708]. [PubMed Central: PMC4279687].
  • 12. Chen J, Lin Y, Cai W, Su T, Wang B, Li J, et al. A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. Dis Esophagus. 2018;31(11). doi: 10.1093/dote/doy043. [PubMed: 29961898].
  • 13. McNamee P, Seymour J. Incorporation of process preferences within the QALY framework: A study of alternative methods. Med Decis Making. 2008;28(3):443-52. doi: 10.1177/0272989X07312473. [PubMed: 18356313].
  • 14. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press; 2015.
  • 15. Garber AM, Sox HC. The role of costs in comparative effectiveness research. Health Aff (Millwood). 2010;29(10):1805-11. doi: 10.1377/hlthaff.2010.0647. [PubMed: 20921479].
  • 16. Ettelt S, Nolte E, Thomson S, Mays N. The systematic use of cost-effectiveness criteria to inform reviews of publicly funded benefits packages. London: Report for the Department of Health, School of Hygiene and Tropical Medicine, Fevrier; 2007.
  • 17. Silva-Illanes N, Espinoza M. Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: A systematic review. Value Health. 2018;21(7):858-73. doi: 10.1016/j.jval.2017.11.010. [PubMed: 30005759].
  • 18. Lao C, Brown C, Rouse P, Edlin R, Lawrenson R. Economic evaluation of prostate cancer screening: A systematic review. Future Oncol. 2015;11(3):467-77. doi: 10.2217/fon.14.273. [PubMed: 25675126].
  • 19. Harewood GC, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of esophageal cancer. Am J Gastroenterol. 2002;97(2):452-8. doi: 10.1111/j.1572-0241.2002.05499.x. [PubMed: 11866287].
  • 20. Pohl H, Sonnenberg A, Strobel S, Eckardt A, Rosch T. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: A decision analysis. Gastrointest Endosc. 2009;70(4):623-31. doi: 10.1016/j.gie.2008.11.047. [PubMed: 19394011].
  • 21. Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, et al. Surgical vs endoscopic management of T1 esophageal adenocarcinoma: A modeling decision analysis. Clin Gastroenterol Hepatol. 2018;16(3):392-400 e7. doi: 10.1016/j.cgh.2017.10.024. [PubMed: 29079222]. [PubMed Central: PMC5852380].
  • 22. Lin CY, Fang HY, Feng CL, Li CC, Chien CR. Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study. Thorac Cancer. 2016;7(3):288-95. doi: 10.1111/1759-7714.12326. [PubMed: 27148413]. [PubMed Central: PMC4846616].
  • 23. Fong Soe Khioe R, Skedgel C, Hart A, Lewis MPN, Alexandre L. Adjuvant statin therapy for esophageal adenocarcinoma: A cost-utility analysis. Pharmacoeconomics. 2018;36(3):349-58. doi: 10.1007/s40273-017-0594-1. [PubMed: 29210031].
  • 24. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-7. doi: 10.1200/JCO.1997.15.1.261. [PubMed: 8996151].
  • 25. Janmaat VT, Bruno MJ, Polinder S, Lorenzen S, Lordick F, Peppelenbosch MP, et al. Cost-effectiveness of cetuximab for advanced esophageal squamous cell carcinoma. PLoS One. 2016;11(4). e0153943. doi: 10.1371/journal.pone.0153943. [PubMed: 27100871]. [PubMed Central: PMC4839693].
  • 26. Shenfine J, McNamee P, Steen N, Bond J, Griffin SM. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess. 2005;9(5):iii. 1-121. doi: 10.3310/hta9050. [PubMed: 15717937].
  • 27. Wenger U, Johnsson E, Bergquist H, Nyman J, Ejnell H, Lagergren J, et al. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: Results of a randomized clinical trial. Eur J Gastroenterol Hepatol. 2005;17(12):1369-77. doi: 10.1097/00042737-200512000-00017. [PubMed: 16292092].
  • 28. Xinopoulos D, Dimitroulopoulos D, Tsamakidis K, Korkolis D, Fotopoulou A, Bazinis A, et al. Palliative treatment of advanced esophageal cancer with metal-covered expandable stents. A cost-effectiveness and quality of life study. J BUON. 2005;10(4):523-8. [PubMed: 17357211].
  • 29. Da Silveira EB, Artifon EL. Cost-effectiveness of palliation of unresectable esophageal cancer. Dig Dis Sci. 2008;53(12):3103-11. doi: 10.1007/s10620-008-0302-2. [PubMed: 18523886].
  • 30. Lee L, Sudarshan M, Li C, Latimer E, Fried GM, Mulder DS, et al. Cost-effectiveness of minimally invasive versus open esophagectomy for esophageal cancer. Ann Surg Oncol. 2013;20(12):3732-9. doi: 10.1245/s10434-013-3103-6. [PubMed: 23838923].
  • 31. Kim SY, Park JH, Kim SG, Woo HK, Park JH, Kim Y, et al. Disparities in utilization of high-volume hospitals for cancer surgery: Results of a Korean population-based study. Ann Surg Oncol. 2010;17(11):2806-15. doi: 10.1245/s10434-010-1133-x. [PubMed: 20535571].
  • 32. Harirchi I, Kolahdoozan S, Hajizadeh S, Safari F, Sedighi Z, Nahvijou A, et al. Esophageal cancer in Iran; a population-based study regarding adequacy of cancer surgery and overall survival. Eur J Surg Oncol. 2014;40(3):352-7. doi: 10.1016/j.ejso.2013.10.011. [PubMed: 24238763].
  • 33. Song PI, Liang H, Fan JH, Wei WQ, Wang GQ, Qiao YL. Long-term survival after esophagectomy for early esophageal squamous cell carcinoma in Linxian, China. J Surg Oncol. 2011;104(2):176-80. doi: 10.1002/jso.21953. [PubMed: 21538356]. [PubMed Central: PMC3129477].
  • 34. McCann P, Stafinski T, Wong C, Menon D. The safety and effectiveness of endoscopic and non-endoscopic approaches to the management of early esophageal cancer: A systematic review. Cancer Treat Rev. 2011;37(1):11-62. doi: 10.1016/j.ctrv.2010.04.006. [PubMed: 20570442].
  • 35. Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, et al. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiov Surg. 2018;156(1):406-413000. doi: 10.1016/j.jtcvs.2018.02.093.
  • 36. Sanghera S, Coast J, Martin RM, Donovan JL, Mohiuddin S. Cost-effectiveness of prostate cancer screening: A systematic review of decision-analytical models. BMC Cancer. 2018;18(1):84. doi: 10.1186/s12885-017-3974-1. [PubMed: 29347916]. [PubMed Central: PMC5773135].
  • 37. Rashidian A, Barfar E, Hosseini H, Nosratnejad S, Barooti E. Cost effectiveness of breast cancer screening using mammography; a systematic review. Iran J Public Health. 2013;42(4):347-57. [PubMed: 23785673]. [PubMed Central: PMC3684720].
  • 38. Becerra V, Avila M, Jimenez J, Cortes-Sanabria L, Pardo Y, Garin O, et al. Economic evaluation of treatments for patients with localized prostate cancer in Europe: A systematic review. BMC Health Serv Res. 2016;16(1):541. doi: 10.1186/s12913-016-1781-z. [PubMed: 27716267]. [PubMed Central: PMC5048403].
  • 39. Nahvijou A, Hadji M, Marnani AB, Tourang F, Bayat N, Weiderpass E, et al. A systematic review of economic aspects of cervical cancer screening strategies worldwide: Discrepancy between economic analysis and policymaking. Asian Pac J Cancer Prev. 2014;15(19):8229-37. doi: 10.7314/APJCP.2014.15.19.8229. [PubMed: 25339011].
  • 40. Allgayer H. Cost-effectiveness of endoscopic ultrasonography in submucosal tumors. Gastrointest Endosc Clin N Am. 1995;5(3):625-9. doi: 10.1016/S1052-5157(18)30429-X. [PubMed: 7582590].
  • 41. Davini IN, Becagli PA, Pani M, Trippoli SA, Peverini DA, Messori AN, et al. Cost-effectiveness of neoadjuvant multimodal therapy in patients with esophageal adenocarcinoma. Oncol Rep. 1997;4(5):1033-7.
  • 42. Dimofte G, Crumpei F, Trifina L, Nicolescu S, Leanca D. Cost-effectiveness of endoscopically placed stents in the palliation of locally advanced esophageal carcinoma. Rom J Gastroenterol. 2004;13(1):17-22. [PubMed: 15054521].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments